The complaint alleges that Zoetis misrepresented its market position and product safety, leading to financial losses for investors once the true state of the company's performance emerged. Specifically, the suit highlights declining prescription growth for the medication Librela following FDA warnings regarding neurological complications in dogs. Furthermore, the company’s dermatology offerings, Apoquel and Cytopoint, reportedly lost significant market share to new competitors, while the Trio product also faced increased pressure from rival treatments.

Shareholders who incurred losses during this period have until July 27, 2026, to contact the firm. Brian Schall of the Los Angeles-based practice is managing inquiries regarding legal rights and potential participation in the suit. As the class has not yet been certified, investors currently remain absent members unless they take affirmative action. Legal counsel is available for consultations regarding the recovery of losses through the Schall Law Firm’s website or office in Century Park East.